EJVIA RECOMMENDS LUNG CANCER AGENT CERITINiB

摘要

The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation for ceritinib (Zykadia), for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small oeil lung cancer in adults with advanced disease that have already been treated with crizotinib. The EMA recommendation for ceritinib is conditional on the manufacturer, Novartis, providing further results from ongoing studies and a comparative phase III study within three years.